KURE
KraneShares MSCI All China Health Care Index ETF·ARCA
--
--(--)
--
--(--)
Key Stats
Assets Under Management
79.76MUSD
Fund Flows (1Y)
20.84MUSD
Dividend Yield
3.97%
Discount/Premium to NAV
1.69%
Shares Outstanding
4.50M
Expense Ratio
0.65%
About KraneShares MSCI All China Health Care Index ETF
Issuer
Krane Funds Advisors, LLC
Brand
KraneShares
Home Page
Inception Date
Jan 31, 2018
Structure
Open-Ended Fund
Index Tracked
MSCI China All Shares Health Care 10/40 Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
Krane Funds Advisors LLC
Distributor
SEI Investments Distribution Co.
KURE holds all types of publicly-issued shares (including A-shares, B-shares, H-shares, N-shares, P-chips, and Red chips) of large- and mid-cap Chinese companies in the healthcare sector. Stocks must meet minimum trading and liquidity requirements and be classified in the healthcare sector under MSCI's GICS standard. Holdings are market cap-weighted with an adjustment based on the proportion of shares available to foreign investors—except for A-shares, which are treated as 100% available. Weights are also modified using a 10/40 capping methodology. Overall, KURE provides exposure to a relatively small slice of the Chinese economy. The index is rebalanced quarterly.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Broad-based
Strategy
Vanilla
Geography
China
Weighting Scheme
Market Cap
Selection Criteria
Market cap
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | -2.65% | -5.16% | +3.50% | +25.93% | -21.07% | -59.77% |
NAV Total Return | -1.39% | -2.73% | +2.25% | +30.47% | -17.36% | -50.88% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
99.16%
Consumer Defensive
0.84%
Healthcare
99.16%
Consumer Defensive
0.84%
Asset
Region
96.36%
3.64%
Category
Ratio
Asia
96.36%
North America
3.64%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Large-Cap Blend
Invests in large-cap companies with both growth and value characteristics. These ETFs offer diversified exposure to stable, well-established companies.
Top 10 Holdings
Symbol
Ratio
BEONE MEDICINES LTD-H
9.52%
JIANGSU HENGRUI PHARMACEUT-A
8.01%
WUXI BIOLOGICS CAYMAN INC
7.64%
INNOVENT BIOLOGICS INC
7.43%
SHENZHEN MINDRAY BIO-MEDIC-A
4.51%
SINO BIOPHARMACEUTICAL
4.24%
AKESO INC
4.07%
CSPC PHARMACEUTICAL GROUP LT
3.89%
HANSOH PHARMACEUTICAL GROUP
3.54%
WUXI APPTEC CO LTD-A
2.97%
Top 10 Weight 55.82%
50 Total Holdings
Is SPY better than KURE?
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2024-12-17 | 2024-12-17 | 2024-12-18 | 0.184 |
| 2023-12-18 | 2023-12-19 | 2023-12-20 | 0.113 |
| 2022-12-28 | 2022-12-29 | 2022-12-30 | 0.010 |
| 2021-12-29 | 2021-12-30 | 2021-12-31 | 4.054 |
| 2018-12-26 | 2018-12-27 | 2018-12-28 | 0.039 |
How Much Does KURE Pay in Dividends?
Premium/Discount Chart
Assets Under Management
Should I buy KURE?
Fund Flows
